What is lapatinib used for?
Lapatinib is used with capecitabine (Xeloda) to treat a certain type of advanced breast cancer in people who have already been treated with other chemotherapy medications.
Is lapatinib generic?
On September 30, 2020, Lupin launched an AB-rated generic version of Novartis’ Tykerb (lapatinib) tablets.
Is lapatinib FDA approved?
The US Food and Drug Administration (FDA) approved lapatinib (Tykerb), in combination with capecitabine (Xeloda), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab (Herceptin).
Who makes lapatinib?
Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly U.S.) and Tyverb (mostly Europe and Russia).
Does lapatinib cause hair loss?
Oral drugs for breast cancer, such as capecitabine (Xeloda) or lapatinib (Tykerb), may cause hair thinning versus the toxic alopecia that can be caused by some intravenous chemotherapeutic agents.
How effective is lapatinib?
According to the findings, lapatinib-based combination treatment was effective and well-tolerated, with a median PFS of 5.8 months, a median OS of 21.5 months, an ORR of 21.7%, a DCR of 87.0% and limited AEs.
Is lapatinib a chemotherapy drug?
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine.
Is lapatinib a monoclonal antibody?
Unlike the large monoclonal antibodies targeting the Her2 pathway, lapatinib is able to cross the blood–brain barrier and has demonstrated activity in patients with brain metastasis.
Is lapatinib a chemotherapy?
Lapatinib – Chemotherapy Drugs – Chemocare.
Is lapatinib cytotoxic?
In conclusion, lapatinib induced cytotoxic and genotoxic effects on MDA-MB-231 cell line. However, laptinib reduced the EGFR protein expression and EGFR signals, it raised the apoptotic cells and TP53 gene signals, which triggered extensive DNA damage.